Nanologica AB (SE:NICA)
:NICA
Top Page
Nanologica AB
(NICA)
Select Model
Select Model
Rating:42Neutral
Price Target:
kr0.34
▼(-54.59% Downside)
Action:ReiteratedDate:03/26/26
The score is primarily constrained by weak financial performance: persistent losses, negative gross profit, and ongoing free-cash-flow burn, alongside a sharply reduced equity base that increases financing risk. Technicals also weigh on the score as the stock trades below all key moving averages with negative MACD. Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Pharma-focused consumable product
Nanologica supplies silica-based separation media used in drug purification and chromatography — a structural demand driver as pharma R&D and manufacturing require reliable consumables. Consumable use creates recurring purchase potential and customer stickiness across labs and production workflows, supporting durable revenue streams if product performance and regulatory acceptance remain strong.
Negative Factors
Negative gross profit and losses
Sustained negative gross profit indicates the core product economics are currently unprofitable. Without durable improvement to yields, pricing, or cost structure, the company cannot generate positive operating margins. Over a multi-month horizon this undermines self-sustainability and forces reliance on external financing or structural business changes to survive.
Read all positive and negative factors
Positive Factors
Negative Factors
Pharma-focused consumable product
Nanologica supplies silica-based separation media used in drug purification and chromatography — a structural demand driver as pharma R&D and manufacturing require reliable consumables. Consumable use creates recurring purchase potential and customer stickiness across labs and production workflows, supporting durable revenue streams if product performance and regulatory acceptance remain strong.
Read all positive factors
Nanologica AB (NICA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr122.96M
Dividend YieldN/A
Average Volume (3M)111.94K
Price to Earnings (P/E)―
Beta (1Y)0.76
Revenue Growth186.74%
EPS Growth73.17%
CountrySE
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.19
Shares Outstanding328,769,840
10 Day Avg. Volume89,035
30 Day Avg. Volume111,941
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.04
Price to Sales (P/S)3.26
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr83.10M
Nanologica AB Business Overview & Revenue Model
Company Description
Nanologica AB (publ), a nanotechnology company, develops nanoporous silica for applications in the life science industry. The company offers nanoporous silica particles for drug development and chromatography separation. It provides NLAB Silica, a...
How the Company Makes Money
Nanologica makes money primarily by selling its silica-based separation and purification products to customers in the pharmaceutical sector, where these materials are used as consumables or process inputs in analytical and preparative workflows (e...
Nanologica AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 21.13M | 14.54M | 1.44M | 1.55M | 12.91M |
| Gross Profit | -49.40M | 4.29M | -76.00K | 3.23M | 4.92M |
| EBITDA | -34.55M | -45.17M | -62.12M | -38.36M | -31.13M |
| Net Income | -51.29M | -65.63M | -75.16M | -55.09M | -50.13M |
Balance Sheet | |||||
| Total Assets | 88.11M | 143.10M | 77.43M | 154.51M | 98.32M |
| Cash, Cash Equivalents and Short-Term Investments | 3.55M | 48.43M | 10.05M | 70.32M | 11.70M |
| Total Debt | 21.47M | 50.94M | 666.00K | 4.69M | 9.79M |
| Total Liabilities | 65.47M | 68.99M | 79.33M | 81.36M | 46.72M |
| Stockholders Equity | 22.64M | 74.11M | -1.90M | 73.16M | 51.60M |
Cash Flow | |||||
| Free Cash Flow | -40.88M | -81.48M | -56.83M | -53.78M | -53.74M |
| Operating Cash Flow | -39.88M | -80.73M | -35.85M | -45.22M | -46.49M |
| Investing Cash Flow | -1.08M | -742.00K | -20.35M | -7.14M | -7.25M |
| Financing Cash Flow | -3.21M | 120.23M | -4.09M | 111.70M | -1.64M |
Nanologica AB Technical Analysis
Negative
0.74
Price Trends
0.41
Negative
0.63
Negative
0.97
Negative
Market Momentum
-0.01
Negative
43.35
Neutral
40.45
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:NICA, the sentiment is Negative. The current price of 0.74 is above the 20-day moving average (MA) of 0.39, above the 50-day MA of 0.41, and below the 200-day MA of 0.97, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 43.35 is Neutral, neither overbought nor oversold. The STOCH value of 40.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:NICA.
Nanologica AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | kr101.08M | -1.81 | -72.82% | ― | 40.91% | 57.92% | |
45 Neutral | kr71.78M | -1.64 | -106.95% | ― | -48.15% | 51.95% | |
44 Neutral | kr135.23M | -1.48 | -52.45% | ― | 2.56% | 52.76% | |
43 Neutral | kr92.64M | -3.17 | -21.31% | ― | -67.00% | 13.62% | |
42 Neutral | kr122.96M | -1.34 | -294.38% | ― | 186.74% | 73.17% | |
42 Neutral | kr82.19M | -2.27 | -120.13% | ― | ― | 49.09% |
* Healthcare Sector Average
SE:NICA
Nanologica AB
0.37
-0.49
-56.61%
SE:ALZ
Alzinova AB
0.60
-1.25
-67.57%
SE:BIOSGN
Biosergen AB
35.00
1.80
5.42%
SE:BIOVIC.B
Biovica International AB Class B
0.35
-0.48
-57.93%
SE:NXTCL
NextCell Pharma AB
1.21
-1.94
-61.52%
SE:SPAGO
Spago Nanomedical AB
0.11
-0.03
-18.80%
Nanologica AB Corporate Events
Nanologica Board Set for Overhaul With New Industry Heavyweights
Mar 10, 2026
Nanologica’s nomination committee has proposed Mark Quick, a partner at Flerie AB with extensive MA and corporate development experience from Recipharm and other pharma companies, and Erik Haeffler, CEO of APL and former manufacturing and su...
Nanologica Raises Capital Through Fully Subscribed Directed Share Issues
Mar 10, 2026
Nanologica AB has completed two directed share issues totaling 34,203,780 new shares, all of which were subscribed and allotted as planned. The issues, priced at SEK 0.40 per share, strengthen the company’s capital base as it pursues growth ...
Nanologica Publishes Information Document for SEK 96 Million Share and Rights Issues
Mar 6, 2026
Nanologica AB has published an information document tied to recently resolved directed share issues totaling about SEK 13.7 million and a rights issue of roughly SEK 82.5 million before costs. The document, prepared under the EU Prospectus Regulat...
Nanologica Shareholders Approve Capital Expansion, Acquisition Financing and Rights Issue
Mar 4, 2026
Nanologica AB’s extraordinary general meeting approved changes to the articles of association, raising the permitted range for share capital and total shares to enable a substantial expansion of the company’s equity base. The meeting a...
Nanologica boosts purification media pipeline, buys Syntagon and launches SEK 96m equity issues
Feb 26, 2026
Nanologica reported 2025 net sales of SEK 21.1 million, up from SEK 14.5 million, while narrowing its full-year operating loss to SEK 46.8 million and loss after tax to SEK 51.3 million, though cash and cash equivalents fell sharply to SEK 3.5 mil...
Nanologica Taps Ardena CEO for Board as Syntagon Deal Deepens Ties
Feb 10, 2026
Nanologica AB, a Swedish life science tools provider, focuses on advanced purification consumables for peptide drugs like insulin and GLP-1 analogues, helping pharmaceutical manufacturers improve productivity and reduce costs in a niche market exp...
Nanologica Launches Fully Secured SEK 96 Million Share Issues to Fund Growth and Reduce Debt
Jan 30, 2026
Nanologica’s board has approved a package of capital measures comprising two directed share issues totaling approximately SEK 13.7 million and a fully secured rights issue of about SEK 82.5 million, all at a subscription price of SEK 0.40 pe...
Nanologica Calls Extraordinary General Meeting to Approve Major Capital Increase and Share Issues
Jan 30, 2026
Nanologica AB has called an Extraordinary General Meeting for March 4, 2026, in Stockholm, where shareholders will vote on a series of capital structure and governance measures, including the adoption of new Articles of Association and multiple sh...
Nanologica Buys Syntagon to Boost API Manufacturing Capacity and Profitable Growth
Jan 29, 2026
Nanologica AB has acquired 100% of Ardena Södertälje AB, which will revert to its original name Syntagon AB, in an all-share deal valued at about SEK 8.6 million, adding a 45-employee contract development and manufacturing operation with...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.